Pigment Epithelial Detachment Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

Read more about this report - Request a Free Sample

Pigment Epithelial Detachment Market Overview

Pigment epithelial detachment is an important retinal condition associated with changes at the interface between the retinal pigment epithelium and underlying structures. Its clinical significance has increased with greater recognition of age-related retinal disorders, improved diagnostic capabilities, and advances in ophthalmic imaging and monitoring approaches. The market is poised to grow at a CAGR of 6.50% during the forecast period of 2026-2035. The market is supported by increasing disease awareness, rising demand for retinal imaging and diagnostic evaluation, and continued development of treatment approaches for associated retinal conditions. Growing adoption of advanced ophthalmic devices and improved access to specialized eye care are further contributing to market expansion.

Pigment Epithelial Detachment Market Growth Analysis and Key Influencers

Pigment Epithelial Detachment Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Pigment Epithelial Detachment Market Growth Drivers

Rising PED Prevalence Strengthens the Market Value

The high prevalence of pigment epithelial detachment (PED) among patients with neovascular age-related macular degeneration (nAMD) is increasing the need for diagnosis, monitoring, and treatment. According to Jennifer I. Lim et al., 2026, PED occurs in approximately 63% to more than 90% of patients with nAMD, with incidence reaching 94% in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy and 86% among those with retinal angiomatous proliferation. The substantial disease burden and associated risk of vision loss are expected to support continued demand for effective PED management and accelerate market growth.

Pigment Epithelial Detachment Market Restraints

Treatment Challenges and Clinical Complexity May Limit the Market Expansion

The complex clinical presentation of PED and differences in treatment response can limit market expansion. Serous, fibrovascular, and mixed PEDs require distinct clinical assessment and management approaches, while fibrovascular PED can cause significant vision loss when associated with untreated choroidal neovascularization. Variability in disease characteristics and the need for repeated imaging and individualized treatment may increase the clinical and economic burden for healthcare providers, potentially slowing the adoption of advanced management approaches.

Pigment Epithelial Detachment Market Opportunities

AI-Based OCT Analysis Creates New Growth Potential for the Market

Advances in artificial intelligence (AI)-based optical coherence tomography (OCT) analysis are creating opportunities for more precise PED detection, quantification, and treatment monitoring. For instance, in September 2024, an AI segmentation system analyzed OCT biomarkers, including PED, in 2,115 eyes from 1,801 patients receiving anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration. The system quantified changes in retinal biomarkers and demonstrated potential for automated, individualized treatment assessment. Wider adoption of AI-enabled imaging could improve clinical decision-making and support future market growth.

Pigment Epithelial Detachment Market Trends

The market is witnessing several trends including AI-enabled imaging, biomarker quantification, personalized treatment, and advanced OCT monitoring.

AI-Enabled OCT Analysis Is Likely to Elevate the Market Growth

The increasing integration of artificial intelligence into OCT imaging is improving the quantitative assessment of PED and other retinal biomarkers. For instance, in September 2024, an AI-based segmentation system evaluated PED, intraretinal fluid, subretinal fluid, and other biomarkers across 2,115 eyes from 1,801 patients with neovascular age-related macular degeneration. Such automated analysis can improve monitoring consistency and support personalized treatment decisions, strengthening demand for advanced diagnostic and monitoring technologies.

Pigment Epithelial Detachment Market Share

Anti-VEGF Therapy by Treatment Type is Poised to Lead the Market

The market is segmented by treatment type into anti-VEGF Therapy, photodynamic therapy (PDT), corticosteroid therapy, laser therapy, combination therapy, and others. Among these, anti-VEGF therapy is expected to lead, supported by its established role in managing neovascular age-related macular degeneration and associated PED. For instance, in August 2025, research reviewing 29 reports covering 28 studies and 8,863 eyes found that OCT biomarkers, including PED, were associated with visual acuity outcomes following anti-VEGF therapy. Continued advances in biomarker-guided treatment are expected to reinforce segment growth.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Pigment Epithelial Detachment Market Analysis by Region

The countries included in the report are the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these markets, the United States is expected to lead, supported by advanced retinal care infrastructure, extensive clinical research, and development of innovative therapies for neovascular age-related macular degeneration. For instance, in March 2026, a Phase 1b study enrolled 164 U.S. patients with diabetic macular edema or wet age-related macular degeneration and reported approximately 50% greater reductions in PED thickness with OLN324 4 mg than with faricimab at Week 12. Continued innovation and clinical development are expected to strengthen market growth in the United States.

Leading Players in the Pigment Epithelial Detachment Market

Pigment Epithelial Detachment Market Segmentation

Key Questions Answered in the Pigment Epithelial Detachment Market Report

• What was the pigment epithelial detachment market value in 2025?
• What is the pigment epithelial detachment market forecast outlook for 2026-2035?
• What are the major factors aiding the pigment epithelial detachment market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major pigment epithelial detachment market trends?
• Which type is expected to dominate the market segment?
• Which treatment type is projected to lead the market segment?
• Which associated disease is anticipated to drive the market segment?
• Which end user is likely to dominate the market segment?
• Who are the key players involved in the pigment epithelial detachment market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews with ophthalmologists, retinal specialists, ophthalmology clinic managers, healthcare procurement professionals, and payer representatives across the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India, focusing on disease management, treatment adoption, diagnostic practices, and unmet needs.
• Secondary Research: Peer-reviewed ophthalmology and retinal disease publications; regulatory information from the US FDA, EMA, PMDA, and CDSCO; clinical trial records from ClinicalTrials.gov; epidemiological data from established public health and ophthalmic sources; and company websites, product information, clinical study results, and pipeline disclosures.
• Validation: Market estimates and epidemiological assessments are triangulated using top-down and bottom-up approaches, supplemented by cross-validation of clinical, commercial, and regulatory data and expert feedback loops.